NEWSROOM
News & Stories
Newsroom
Press Releases
Agendia Unveils New Real-World-Evidence from FLEX, Highlighting the Expanding Utility of MammaPrint and BluePrint for Predicting Neoadjuvant Chemosensitivity and Potential Resistance to CDK4/6 Inhibition in Early-Stage Breast Cancer at SABCS 2024
Gene expression analysis reveals MammaPrint® as the only commercially available genomic signature that may identify patient subgroups with resistance to CDK4/6 inhibition New real world evidence from FLEX adds to the growing body of Read More
Agendia Demonstrates MammaPrint Utility in Predicting Chemotherapy Benefit Over 5 Years in Patients with HR+HER2- Early Breast Cancer at SABCS 2024
New data reinforces findings from MINDACT supporting MammaPrint® in predicting chemotherapy benefit for distant recurrence free interval among patients with HR+HER2-early-stage breast cancer IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – December 11, 2024 – Read More
Agendia Announces Publication Validating MammaPrint Utility in Prediction of Extended Endocrine Therapy Benefit
A secondary analysis of the randomized controlled trial, IDEAL, confirms results from NSABP B-42 demonstrating MammaPrint is predictive of extended endocrine therapy benefit IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – December 2, 2024 – Read More
Newsroom
News, Stories & Breast Cancer Blog
Coffee with America: Dr. William Audeh for Agendia Breast Cancer Subtyping
Discover why understanding the specific characteristics of breast cancer is crucial for developing personalized treatment strategies that can significantly improve outcomes. Dr. William Audeh, a leading medical oncologist specializing in breast cancer and Agendia Read More
Genomic Testing Transforms Breast Cancer Care and Treatment Success
In an insightful interview with Dr. William Audeh, MD, MS, Chief Medical Officer at Agendia, featured in ONCOLife, we explore the pioneering strides in genomic testing within breast cancer treatment. Dr. Audeh, shares his Read More
Recognizing Common Breast Cancer Symptoms & the Importance of Early Detection
Breast cancer is the most common cancer among women, with about 1 in 8 women being diagnosed in their lifetime.[1] It also accounts for nearly 30% of all new female cancer diagnoses each year, Read More
Faith Over Fear, My Life Matters (Winter 2023-2024)
A journey to inclusive breast cancer care through faith, science, and personalized testing.
Read the ArticleArticle: Disparities in Survival Outcomes Revealed w/ BluePrint + MammaPrint
“These data highlight the importance of genomic testing to help optimize treatment and reduce outcome disparities in Black women.”
Read the ArticleAgendia Touting New Data Showing Pre-Surgery Use of MammaPrint, BluePrint
Research showing that Agendia's MammaPrint and BluePrint tests can predict which breast cancer patients are likely to have the cancer in their lymph nodes down-staged following neoadjuvant chemotherapy has the company optimistic about a potentially new use for its gene expression tests.
Read the Article
